fda tirzepatide shortage resolved oct 2 2024 reconsidering its decision to take off its drug list The FDA should require negative

An update on peptide-based therapies for type 2 diabetes and obesity

Ziltive kimab is an IL-6 monoclonal antibody specifically developed for cardiovascular risk reduction

To determine the best approach for your unique health goals, we invite you to take our AI quiz, which will help you identify the most suitable supplements for your needs

In STEP 1-3 clinical trials, a weekly dose of 2.4 mg semaglutide resulted in a 49% reduction in C-reactive protein (CRP) levels, while a 1 mg weekly dose led to a 42% decrease, compared to placebo after 68 weeks

Chewing it is easy, but you are advised to drink water afterward

As obesity is linked with a multitude of health issues, including type 2 diabetes, cardiovascular diseases, and hormonal imbalances, the search for effective weight loss solutions has been relentless